NextCure Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BELTSVILLE, Md., May 13, 2019 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $15.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 750,000 shares of common stock. Including the option exercise, the gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were $86.25 million. All of the shares in the offering were offered by NextCure. NextCure’s common stock is listed on The Nasdaq Global Select Market under the ticker symbol “NXTC.”

Morgan Stanley, BofA Merrill Lynch and Piper Jaffray & Co. acted as joint book-running managers of the offering.

A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission (SEC) on May 8, 2019. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by visiting EDGAR on the SEC’s website at www.sec.gov or from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, North Carolina 28255-0001, Attn: Prospectus Department, or by email at dg.prospectus_requests@baml.com; or Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, Minnesota, 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. www.nextcure.com

Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
SVP, Corporate Development
(240) 762-6486
 

Media Inquiries
Shai Biran, Ph.D.
MacDougall
(781) 235-3060
Source: GlobeNewswire News Room

Subscribe to Money News Alerts

This article by Money News National is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Money News National has no position in the stocks mentioned. Thank you for reading.

__________________

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

LEAVE A REPLY

Please enter your comment!
Please enter your name here